ホーム>>Infectious Disease>> Bacterial Diseases>>Tilmicosin-d3

Tilmicosin-d3 (Synonyms: LY-177370-d3; EL-870-d3)

カタログ番号GC49076

チルミコシンの定量化のための内部標準

Products are for research use only. Not for human use. We do not sell to patients.

Tilmicosin-d3 化学構造

Cas No.: N/A

サイズ 価格 在庫数 個数
5 mg
$369.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Tilmicosin-d3 is intended for use as an internal standard for the quantification of tilmicosin by GC- or LC-MS. Tilmicosin is a macrolide antibiotic.1 It is active against macrolide-susceptible strains of M. haemolytica, P. multocida, and E. coli (MICs = 4, 4, and 128 µM, respectively), as well as a hyperpermeable strain of E. coli (MIC = 2 µM), and inhibits bacterial protein synthesis (IC50 = 0.36 µM). Tilmicosin (75 mg/kg) increases serum creatine kinase (CK), the MB isoform of CK (CK-MB), and malondialdehyde (MDA) levels in mice, indicating cardiotoxicity.2 Formulations containing tilmicosin have been used in the treatment of respiratory diseases in sheep and cattle.

1.Andersen, N.M., Poehlsgaard, J., Warrass, R., et al.Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolidesAntimicrob. Agents Chemother.56(11)6033-6036(2012) 2.Kart, A., Yapar, K., Karapehlivan, M., et al.The possible protective effect of ?-carnitine on tilmicosin-induced cardiotoxicity in miceJ. Vet. Med. A Physiol. Pathol. Clin. Med.54(3)144-146(2007)

レビュー

Review for Tilmicosin-d3

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tilmicosin-d3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.